Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Pulmonology Reports
Published in: Current Pulmonology Reports 3/2018

Open Access 01-09-2018 | Bronchiectasis (A Schmid, Section Editor)

Risk of Bacterial Transmission in Bronchiectasis Outpatient Clinics

Authors: Philip Mitchelmore, Catherine Wilson, David Hettle

Published in: Current Pulmonology Reports | Issue 3/2018

Login to get access

Abstract

Purpose of Review

The purpose of this review is to discuss the risk of bacterial cross-infection for bronchiectasis patients in the outpatient setting. Cross-infection has primarily been a matter of concern in cystic fibrosis (CF). There is considerable evidence of transmission of pathogens between CF patients, and this has led to guideline recommendations advocating strict segregation policies. Guidelines in bronchiectasis do not specifically address the issue of cross-infection. If cross-infection is prevalent, it may have significant implications for patients and the practical running of specialist care.

Recent Findings

Multiple UK-based studies have now published evidence of cross-infection with Pseudomonas aeruginosa within cohorts of bronchiectasis patients; however, the risk does not appear to be high. There is also evidence suggesting cross-infection from CF patients to bronchiectasis patients.

Summary

The current evidence for cross-infection in bronchiectasis is limited, but suggests a small risk with Pseudomonas aeruginosa. Longitudinal studies looking at Pseudomonas aeruginosa and other pathogens are now required.
Literature
1.
2.
Goeminne PC, De Soyza A. Bronchiectasis: how to be an orphan with many parents? Eur Respir J. 2016;47(1):10–3.CrossRefPubMed
3.
Weycker D, Edelsberg J, Osler G, Tino G. Prevalence and economic burden of bronchiectasis. Clin Pulm Med. 2005;12(4):205–9.CrossRef
4.
Ringshausen FC, de Roux A, Diel R, Hohmann D, Welte T, Rademacher J. Bronchiectasis in Germany: a population-based estimation of disease prevalence. Eur Respir J. 2015;46(6):1805–7.CrossRefPubMed
5.
• Quint JK, Millett ER, Joshi M, Navaratnam V, Thomas SL, Hurst JR, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J. 2016;47(1):186–93. Demonstrates the increasing relevance of bronchiectasis in clinical practise. CrossRefPubMed
6.
Anwar GA, McDonnell MJ, Worthy SA, Bourke SC, Afolabi G, Lordan J, et al. Phenotyping adults with non-cystic fibrosis bronchiectasis: a prospective observational cohort study. Respir Med. 2013;107(7):1001–7.CrossRefPubMed
7.
O’Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax. 2000;55(8):635–42.CrossRefPubMedPubMedCentral
8.
Gatheral T, Kumar N, Sansom B, Lai D, Nair A, Vlahos I, et al. COPD-related bronchiectasis: independent impact on disease course and outcomes. COPD. 2014;11(6):605–14.CrossRefPubMed
9.
Cole PJ. Inflammation: a two-edged sword—the model of bronchiectasis. Eur J Respir Dis Suppl. 1986;147:6–15.PubMed
10.
Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J. 2015;45(5):1446–62.CrossRefPubMed
11.
Cole P. The damaging role of bacteria in chronic lung infection. J Antimicrob Chemother. 1997;40(Suppl A):5–10.CrossRefPubMed
12.
Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med. 2014;189(5):576–85.CrossRefPubMedPubMedCentral
13.
Goeminne PC, Scheers H, Decraene A, Seys S, Dupont LJ. Risk factors for morbidity and death in non-cystic fibrosis bronchiectasis: a retrospective cross-sectional analysis of CT diagnosed bronchiectatic patients. Respir Res. 2012;13:21.CrossRefPubMedPubMedCentral
14.
McDonnell MJ, Jary HR, Perry A, MacFarlane JG, Hester KL, Small T, et al. Non cystic fibrosis bronchiectasis: a longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. Respir Med. 2014;109(6):716–26.CrossRefPubMed
15.
Nicotra MB, Rivera M, Dale AM, Shepherd R, Carter R. Clinical, pathophysiologic, and microbiologic characterization of bronchiectasis in an aging cohort. Chest. 1995;108(4):955–61.CrossRefPubMed
16.
Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JDA. Comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann Am Thorac Soc. 2015;12(11):1602–11.PubMed
17.
Thomassen MJ, Demko CA, Doershuk CF, Root JM. Pseudomonas aeruginosa isolates: comparisons of isolates from campers and from sibling pairs with cystic fibrosis. Pediatr Pulmonol. 1985;1(1):40–5.CrossRefPubMed
18.
Grothues D, Koopmann U, von der Hardt H, Tümmler B. Genome fingerprinting of Pseudomonas aeruginosa indicates colonization of cystic fibrosis siblings with closely related strains. J Clin Microbiol. 1988;26(10):1973–7.PubMedPubMedCentral
19.
Tummler B, Koopmann U, Grothues D, Weissbrodt H, Steinkamp G, von der Hardt H. Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis patients. J Clin Microbiol. 1991;29(6):1265–7.PubMedPubMedCentral
20.
Ojeniyi B, Frederiksen B, Hoiby N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol. 2000;29(3):177–81.CrossRefPubMed
21.
Hunfeld KP, Schmidt C, Krackhardt B, Posselt HG, Bargon J, Yahaf Y, et al. Risk of Pseudomonas aeruginosa cross-colonisation in patients with cystic fibrosis within a holiday camp—a molecular-epidemiological study. Wien Klin Wochenschr. 2000;112(7):329–33.PubMed
22.
LiPuma JJ, Dasen SE, Nielson DW, Stern RC, Stull TL. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet. 1990;336(8723):1094–6.CrossRefPubMed
23.
Pegues DA, Carson LA, Tablan OC, FitzSimmons SC, Roman SB, Miller JM, et al. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. Summer Camp Study Group J Pediatr. 1994;124(5 Pt 1):694–702.
24.
Millar-Jones L, Paull A, Saunders Z, Goodchild MC. Transmission of Pseudomonas cepacia among cystic fibrosis patients. Lancet. 1992;340(8817):491.CrossRefPubMed
25.
Smith DL, Gumery LB, Smith EG, Stableforth DE, Kaufmann ME, Pitt TL. Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: evidence of person-to-person transmission. J Clin Microbiol. 1993;31(11):3017–22.PubMedPubMedCentral
26.
Corkill JE, Sisson PR, Smyth A, Deveney J, Freeman R, Shears P, et al. Application of pyrolysis mass spectroscopy and SDS-PAGE in the study of the epidemiology of Pseudomonas cepacia in cystic fibrosis. J Med Microbiol. 1994;41(2):106–11.CrossRefPubMed
27.
Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, et al. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet. 1996;348(9028):639–42.CrossRefPubMed
28.
Pedersen SS, Koch C, Høiby N, Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother. 1986;17(4):505–16.CrossRefPubMed
29.
Ledson MJ, Gallagher MJ, Jackson M, Hart CA, Walshaw MJ. Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre. Thorax. 2002;57(2):142–5.CrossRefPubMedPubMedCentral
30.
Aaron SD, Vandemheen KL, Ramotar K, Giesbrecht-Lewis T, Tullis E, Freitag A, et al. Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. JAMA. 2010;304(19):2145–53.CrossRefPubMed
31.
Al-Aloul M, Crawley J, Winstanley C, Hart CA, Ledson MJ, Walshaw MJ. Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax. 2004;59(4):334–6.CrossRefPubMedPubMedCentral
32.
Saiman L, Siegel JD, LiPuma JJ, Brown RF, Bryson EA, Chambers MJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol. 2014;35(Suppl 1):S1–s67.CrossRefPubMed
33.
Smyth AR, Bell SC, Bojcin S, Bryon M, Duff A, Flume P, et al. European cystic fibrosis society standards of care: best practice guidelines. J Cyst Fibros. 2014;13(Suppl 1):S23–42.CrossRefPubMed
34.
Frederiksen B, Koch C, Hoiby N. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995). Pediatr Pulmonol. 1999;28(3):159–66.CrossRefPubMed
35.
Ashish A, Shaw M, Winstanley C, Humphreys L, Walshaw MJ. Halting the spread of epidemic pseudomonas aeruginosa in an adult cystic fibrosis centre: a prospective cohort study. JRSM Short Rep. 2013;4(1):1–8.CrossRefPubMedPubMedCentral
36.
Griffiths AL, Wurzel DF, Robinson PJ, Carzino R, Massie J. Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic. J Cyst Fibros. 2012;11(1):49–52.CrossRefPubMed
37.
Thomassen MJ, Demko CA, Doershuk CF, Stern RC, Klinger JD. Pseudomonas cepacia: decrease in colonization in patients with cystic fibrosis. Am Rev Respir Dis. 1986;134(4):669–71.PubMed
38.
Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet. 2013;381(9877):1551–60.CrossRefPubMedPubMedCentral
39.
Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I, Brown KP, Moreno P, et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science. 2016;354(6313):751–7.CrossRefPubMedPubMedCentral
40.
Waters V, Zlosnik JE, Yau YC, Speert DP, Aaron SD, Guttman DS. Comparison of three typing methods for Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 2012;31(12):3341–50.CrossRefPubMed
41.
Romling U, Kader A, Sriramulu DD, Simm R, Kronvall G. Worldwide distribution of Pseudomonas aeruginosa clone C strains in the aquatic environment and cystic fibrosis patients. Environ Microbiol. 2005;7(7):1029–38.CrossRefPubMed
42.
Romling U, Wingender J, Müller H, Tümmler B. A major Pseudomonas aeruginosa clone common to patients and aquatic habitats. Appl Environ Microbiol. 1994;60(6):1734–8.PubMedPubMedCentral
43.
Knibbs LD, Johnson GR, Kidd TJ, Cheney J, Grimwood K, Kattenbelt JA, et al. Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis. Thorax. 2014;69(8):740–5.CrossRefPubMedPubMedCentral
44.
Schaffer K. Epidemiology of infection and current guidelines for infection prevention in cystic fibrosis patients. J Hosp Infect. 2015;89(4):309–13.CrossRefPubMed
45.
Clifton IJ, Fletcher LA, Beggs CB, Denton M, Conway SP, Peckham DG. An aerobiological model of aerosol survival of different strains of Pseudomonas aeruginosa isolated from people with cystic fibrosis. J Cyst Fibros. 2010;9(1):64–8.CrossRefPubMed
46.
Panagea S, Winstanley C, Walshaw MJ, Ledson MJ, Hart CA. Environmental contamination with an epidemic strain of Pseudomonas aeruginosa in a Liverpool cystic fibrosis centre, and study of its survival on dry surfaces. J Hosp Infect. 2005;59(2):102–7.CrossRefPubMed
47.
Jones AM, Dodd ME, Govan JR, Doherty CJ, Smith CM, Isalska BJ, et al. Prospective surveillance for Pseudomonas aeruginosa cross-infection at a cystic fibrosis center. Am J Respir Crit Care Med. 2005;171(3):257–60.CrossRefPubMed
48.
Griffiths AL, Jamsen K, Carlin JB, Grimwood K, Carzino R, Robinson PJ, et al. Effects of segregation on an epidemic Pseudomonas aeruginosa strain in a cystic fibrosis clinic. Am J Respir Crit Care Med. 2005;171(9):1020–5.CrossRefPubMed
49.
•• Hilliam Y, Moore MP, Lamont IL, Bilton D, Haworth CS, Foweraker J, et al. Pseudomonas aeruginosa adaptation and diversification in the non-cystic fibrosis bronchiectasis lung. Eur Respir J. 2017;49(4):1602108. https://​doi.​org/​10.​1183/​13993003.​02108-2016. Multi-centre whole genome sequencing study of bronchiectasis in the UK. Raises concerns of possible cross-infection with P. aeruginosa in a bronchiectasis cohorts. CrossRefPubMedPubMedCentral
50.
Macia MD, Blanquer D, Togores B, Sauleda J, Pérez JL, Oliver A. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother. 2005;49(8):3382–6.CrossRefPubMedPubMedCentral
51.
Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65(Suppl 1):i1–58.CrossRefPubMed
52.
53.
•• De Soyza A, Perry A, Hall AJ, Sunny SS, Walton KE, Mustafa N, et al. Molecular epidemiological analysis suggests cross-infection with Pseudomonas aeruginosa is rare in non-cystic fibrosis bronchiectasis. Eur Respir J. 2014;43(3):900–3. Demonstrated probable rare cross-infection with P. aeruginosa in a specialist bronchiectasis service. CrossRefPubMed
54.
•• Mitchelmore PJ, Randall J, Bull MJ, Moore KA, O’Neill PA, Paszkiewicz K, et al. Molecular epidemiology of Pseudomonas aeruginosa in an unsegregated bronchiectasis cohort sharing hospital facilities with a cystic fibrosis cohort. Thorax. https://​doi.​org/​10.​1136/​thoraxjnl-2016-209889. Evidence of cross-infection with P. aeruginosa found between three patients. No evidence of cross-infection with the local segregated CF cohort.
55.
Mitchelmore P, Brown A, Sheldon C, Scotton C, Bull M, Mahenthiralingam E, et al. S113: an epidemiological review of strains of Pseudomonas aeruginosa in a non-cystic fibrosis bronchiectasis cohort. Thorax. 2015;70(Suppl 3):A65.CrossRef
56.
Robinson P, Carzino R, Armstrong D, Olinsky A. Pseudomonas cross-infection from cystic fibrosis patients to non-cystic fibrosis patients: implications for inpatient care of respiratory patients. J Clin Microbiol. 2003;41(12):5741.CrossRefPubMedPubMedCentral
57.
• Keil C, Manzoor S, Gossain S, Hardy K, Whitehouse JL. P269: acquisition of epidemic pseudomonas aeruginosa strains in non-cf bronchiectasis patients. Thorax. 2016;71(Suppl 3):A234. Conference abstract data suggesting a bronchiectasis cohort susceptible to cross-infection from the local cystic fibrosis cohort. CrossRef
58.
•• Chalmers JD, Ringshausen FC, Harris B, Elborn JS, Posthumus A, Haworth CS, et al. Cross-infection risk in patients with bronchiectasis: a position statement from the European Bronchiectasis Network (EMBARC), EMBARC/ELF patient advisory group and European Reference Network (ERN-Lung) Bronchiectasis Network. Eur Resp J. 2018;51(1):1701937. https://​doi.​org/​10.​1183/​13993003.​01937-2017. First position statement on the topic by a major international network or organisation. CrossRef
59.
Aliberti S, Masefield S, Polverino E, De Soyza A, Loebinger MR, Menendez R, et al. Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration. Eur Respir J. 2016;48(3):632–47.CrossRefPubMed
60.
Haworth CS, Banks J, Capstick T, Fisher AJ, Gorsuch T, Laurenson IF, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(Suppl 2):ii1–ii64.CrossRefPubMed
Metadata
Title
Risk of Bacterial Transmission in Bronchiectasis Outpatient Clinics
Authors
Philip Mitchelmore
Catherine Wilson
David Hettle
Publication date
01-09-2018
Publisher
Springer US
Published in
Current Pulmonology Reports / Issue 3/2018
Electronic ISSN: 2199-2428
DOI
https://doi.org/10.1007/s13665-018-0203-6

Other articles of this Issue 3/2018

Current Pulmonology Reports 3/2018 Go to the issue

Lung Cancer (R Mudad, Section Editor)

Treatment of Advanced Non-Small Cell Lung Cancer in the Era of Targeted Therapy

Bronchiectasis (A Schmid, Section Editor)

Risk of Development of Resistance in Patients with Non-Cystic Fibrosis Bronchiectasis Treated with Inhaled Antibiotics

Lungs Transplant (R Bag, Section Editor)

Rising to the Challenge of Unmet Need: Expanding the Lung Donor Pool

Lungs Transplant (R Bag, Section Editor)

It's What’s Inside that Counts: Body Composition and Lung Transplantation

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits